Lead Product(s) : Treg Cell Therapy
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Sonoma Biotherapeutics Receives $45M Regeneron Milestone
Details : The collaboration will bring together Regeneron’s VelociSuite technologies to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $75.0 million
September 04, 2024
Lead Product(s) : Treg Cell Therapy
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : Naloxegol Oxalate
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Grunenthal
Deal Size : $250.0 million
Deal Type : Acquisition
Grünenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma
Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.
Product Name : Movantik
Product Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Naloxegol Oxalate
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Grunenthal
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women
Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Microbiome-based Therapy
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the collaboration, Ferring will get exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
December 11, 2023
Lead Product(s) : Microbiome-based Therapy
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Gut-brain Axis Based Drug
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2023
Lead Product(s) : Gut-brain Axis Based Drug
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Verily’s proprietary Immune Profiler is a next generation immune mapping platform that will be used to identify GPCR targets that represent new opportunities to modulate immune cell function and ameliorate disease pathology.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Amgen Inc
Deal Size : $530.0 million
Deal Type : Collaboration
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease
Details : Under the terms of agreement, Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Cro...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $30.0 million
May 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Amgen Inc
Deal Size : $530.0 million
Deal Type : Collaboration
Lead Product(s) : Treg-based Cell Therapy
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Details : Regeneron and Sonoma will research and develop Treg-based Cell Therapies for ulcerative colitis, Crohn’s disease and two other undisclosed indications, through VelociSuite® technologies for the discovery and characterization of fully human antibodies ...
Product Name : Undislcosed
Product Type : Cell and Gene therapy
Upfront Cash : $75.0 million
March 28, 2023
Lead Product(s) : Treg-based Cell Therapy
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration